Injury and recovery claims

What human evidence and regulatory status actually support.

Studies in cells and animals cannot show that KPV, BPC-157 or related products heal a specific injury site in people. They also do not make any of these substances a proven “beginner peptide” or recovery stack.

Source-based editorial review; independent clinical review pending. Read the sources.

Evidence by peptide

• KPV: KPV is a three-amino-acid fragment of alpha-MSH. So far, the studies cited here involve cells and animals. They cannot tell us whether oral, topical or injected KPV treats inflammatory bowel disease, skin disease or systemic inflammation in people. [1–3]

Common Questions

• Does this page recommend a dose or stack?

  No. Trial protocols describe research, and approved-product instructions apply only to the named formulation and labeled population.

• Can animal, cell or mechanistic findings prove a human benefit?

  No. They can justify further research but cannot be rewritten as a demonstrated outcome in people.

Sources and study limits

1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration
2. Unapproved Drugs U.S. Food and Drug Administration
3. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models Kannengiesser K, et al. (2008)
4. The alpha-MSH-derived tripeptide KPV decreases intestinal inflammation Dalmasso G, et al. (2008)
5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: KPV U.S. Food and Drug Administration

← Browse all peptides

Educational evidence summary. FDA approval, investigational status, and compounding are separate categories. Use the current label and a licensed clinician for patient-specific decisions.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify